Literature DB >> 15380527

Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes.

Valeria Judkowski1, Enrique Rodriguez, Clemencia Pinilla, Emma Masteller, Jeffrey A Bluestone, Nora Sarvetnick, Darcy B Wilson.   

Abstract

NOD mice spontaneously develop insulitis and type 1 diabetes (T1D) mellitus similar to humans. Insulitis without overt disease occurs in the BDC2.5 TCR-transgenic NOD mice that express the rearranged TCR alpha- and beta-chain genes of a diabetogenic T cell clone reactive to an unknown beta cell autoantigen. A previous study identified an extensive panel of peptides that are highly active in stimulating T cells from transgenic BDC2.5 mice in culture. However, none of these peptides cause active disease in NOD and BDC2.5 animals or in NOD recipients of adoptively transferred BDC2.5 T cells following direct immunization in vivo. We show that direct immunization of transgenic BDC2.5 mice causes many BDC2.5 T cells to become activated and apoptotic. Strikingly, soluble peptides administered to recipients of activated, highly pathogenic BDC2.5 T cells results in protection from disease. These results suggest that high affinity peptide analogues of autoimmune epitopes might be useful as therapeutic modulators in active autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15380527     DOI: 10.1016/j.clim.2004.03.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

1.  Engineering antigens for in situ erythrocyte binding induces T-cell deletion.

Authors:  Stephan Kontos; Iraklis C Kourtis; Karen Y Dane; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

2.  Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.

Authors:  Kelan A Hlavaty; Derrick P McCarthy; Eiji Saito; Woon Teck Yap; Stephen D Miller; Lonnie D Shea
Journal:  Biomaterials       Date:  2015-10-21       Impact factor: 12.479

3.  Inducing immune tolerance: a focus on Type 1 diabetes mellitus.

Authors:  Dan Xu; Suchitra Prasad; Stephen D Miller
Journal:  Diabetes Manag (Lond)       Date:  2013-09-01

4.  Nanoparticles Containing an Insulin-ChgA Hybrid Peptide Protect from Transfer of Autoimmune Diabetes by Shifting the Balance between Effector T Cells and Regulatory T Cells.

Authors:  Braxton L Jamison; Tobias Neef; Andrew Goodspeed; Brenda Bradley; Rocky L Baker; Stephen D Miller; Kathryn Haskins
Journal:  J Immunol       Date:  2019-05-20       Impact factor: 5.422

Review 5.  Tolerogenic Nanoparticles to Treat Islet Autoimmunity.

Authors:  Tobias Neef; Stephen D Miller
Journal:  Curr Diab Rep       Date:  2017-08-08       Impact factor: 4.810

6.  Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8+ T cell responses in type 1 diabetes.

Authors:  Xinyu Xu; Lingling Bian; Min Shen; Xin Li; Jing Zhu; Shuang Chen; Lei Xiao; Qingqing Zhang; Heng Chen; Kuanfeng Xu; Tao Yang
Journal:  Diabetologia       Date:  2017-09-08       Impact factor: 10.122

7.  Immune Modulation and Prevention of Autoimmune Disease by Repeated Sequences from Parasites Linked to Self Antigens.

Authors:  Fabiola Puentes; Katharina Dickhaut; Maria Hofstätter; Jennifer Pfeil; Uta Lauer; Alf Hamann; Ute Hoffmann; Kirsten Falk; Olaf Rötzschke
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-12       Impact factor: 4.147

Review 8.  Novel delivery mechanisms for antigen-specific immunotherapy.

Authors:  Tobias Neef; Stephen D Miller
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2021-08-01       Impact factor: 3.626

9.  Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells.

Authors:  Martin A Leon; Rebuma Firdessa-Fite; Justin K Ruffalo; Chad J Pickens; Joshua O Sestak; Remi J Creusot; Cory Berkland
Journal:  ACS Chem Biol       Date:  2019-07-01       Impact factor: 4.634

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.